Search

Your search keyword '"Scholz, Christian W"' showing total 140 results
Start Over Author "Scholz, Christian W"
140 results on '"Scholz, Christian W"'

1. The addition of bortezomib to rituximab, high-dose cytarabine and dexamethasone in relapsed or refractory mantle cell lymphoma—a randomized, open-label phase III trial of the European mantle cell lymphoma network

Author

Fischer, Luca, Jiang, Linmiao, Dürig, Jan, Schmidt, Christian, Stilgenbauer, Stephan, Bouabdallah, Krimo, Solal-Celigny, Philippe, Scholz, Christian W., Feugier, Pierre, de Wit, Maike, Trappe, Ralf Ulrich, Hallek, Michael, Graeven, Ullrich, Hänel, Mathias, Hoffmann, Martin, Delwail, Vincent, Macro, Margaret, Greiner, Jochen, Giagounidis, Aristoteles A. N., Dargel, Beate, Durot, Eric, Foussard, Charles, Silkenstedt, Elisabeth, Weigert, Oliver, Pott, Christiane, Klapper, Wolfram, Hiddemann, Wolfgang, Unterhalt, Michael, Hoster, Eva, Ribrag, Vincent, and Dreyling, Martin

Published
2024
Full Text
View/download PDF

2. Adressen

Author

Eucker, Jan, primary, Scholz, Christian W., additional, Bathon, Melanie, additional, Busse, Antonia, additional, Dieing, Annette, additional, Eucker, Jan, additional, Flath, Bernd, additional, Folprecht, Gunnar, additional, Habbel, Jan-Piet, additional, Heidel, Florian, additional, Hochhaus, Andreas, additional, Hübel, Kai, additional, Jann, Henning, additional, Jehn, Christian, additional, Klinghammer, Konrad, additional, Knauf, Wolfgang, additional, Kolb, Hans-Jochem, additional, Kroenlein, Hannes, additional, Kubasch, Anne Sophie, additional, Lüftner, Diana, additional, Meyer, Oliver, additional, Möhlig, Matthias, additional, Naumann, Ralph, additional, Nogai, Axel, additional, Ochsenreither, Sebastian, additional, Oettle, Helmut, additional, Pape, Ulrich-Frank, additional, Platzbecker, Uwe, additional, Rank, Andreas, additional, Reichardt, Peter, additional, Rick, Oliver, additional, Rieke, Damian, additional, Riess, Hanno, additional, Ruhnke, Markus, additional, Schaich, Markus, additional, Schalhorn, Andreas, additional, Schmälter, Ann-Kristin, additional, Schmidt-Graf, Friederike, additional, Schmittel, Alexander, additional, Schrezenmeier, Hubert, additional, Schulz, Carsten-Oliver, additional, Speiser, Dorothee, additional, Vogel, Arndt, additional, Baumgarten, Louisa von, additional, and Welland, Dr. med. Sabrina, additional

Published
2024
Full Text
View/download PDF

3. International validation of a health-related quality-of-life questionnaire for Hodgkin lymphoma: the EORTC QLQ-HL27

Author

Oerlemans, Simone, Efficace, Fabio, Shamieh, Omar, Cardoso Borges, Fabio, de Jong, Corine, Dong, Dong, Lehmann, Jens, Malak, Sandra, Petranovic, Duska, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Griskevicius, Laimonas, Nagele, Eva, Bredart, Anne, Carvalho, Elisabete, Xochelli, Aliki, Agelink van Rentergem, Joost, Alrjoob, Waleed, Mueller, Anja, Freitas, Ana Carolina, Cocks, Kim, Creutzberg, Carien, Kyriakou, Charalampia, and van de Poll-Franse, Lonneke

Published
2023
Full Text
View/download PDF

5. A German-Wide Systematic Study on Mobilization and Collection of Hematopoietic Stem Cells in Poor Mobilizer Patients with Multiple Myeloma prior to Autologous Stem Cell Transplantation

Author

Bittrich, Max, primary, Kriegsmann, Katharina, additional, Tietze-Stolley, Carola, additional, Movassaghi, Kamram, additional, Grube, Matthias, additional, Vucinic, Vladan, additional, Wehler, Daniela, additional, Burchert, Andreas, additional, Schmidt-Hieber, Martin, additional, Rank, Andreas, additional, Dürk, Heinz A., additional, Metzner, Bernd, additional, Kimmich, Christoph, additional, Hentrich, Marcus, additional, Kunz, Christian, additional, Hartmann, Frank, additional, Khandanpour, Cyrus, additional, de Wit, Maike, additional, Holtick, Udo, additional, Kiehl, Michael, additional, Stoltefuß, Andrea, additional, Kiani, Alexander, additional, Naumann, Ralph, additional, Scholz, Christian W., additional, Tischler, Hans-Joachim, additional, Görner, Martin, additional, Brand, Franziska, additional, Ehmer, Martin, additional, and Kröger, Nicolaus, additional

Published
2023
Full Text
View/download PDF

15. An open-label, phase I/II trial to determine the maximum tolerated dose and investigate safety, pharmacokinetics and efficacy of BI 836858, an unconjugated anti-CD33 monoclonal antibody, in combination with decitabine in patients with acute myeloid leukemia

Author

Fiedler, Walter, Montesinos, Pau, Schliemann, Christoph, Middeke, Jan, Vasu, Sumithira, Scholz, Christian W, Esteve, Jordi, Mondal, Shoubhik, Ruter, Bjorn, Burkard, Ute, Osswald, Annika, and Blum, William

Subjects
Hematology
Published
2022

16. Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Author

Jaramillo Segura, Sonia, Wass, Maxi, Schaffrath, Judith, Rieger, Kathrin, Nogai, Axel, Hänel, Mathias, Herbst, Regina, Stölzel, Friedrich, Röllig, Christoph, Jost, Edgar, Schlenk, Richard F., Noppeney, Richard, Brandts, Christian H., Krug, Utz, Götze, Katharina S., Buske, Sebastian, Florschütz, Axel, Schubert, Jörg, Opitz, Bernhard, Mohren, Martin, Eßeling, Eva, von Witzendorff, Stephan, Subklewe, Marion, Kaufmann, Martin, Frickhofen, Norbert, Scholz, Christian W., Schäfer-Eckart, Kerstin, Kunzmann, Volker, Schmidt-Hieber, Martin, Sayer, Herbert G., Rank, Andreas, Hemmati, Philipp, Schüler, Frank, Kowoll, Simone, Scheller, Marina, Steighardt, Jörg, Edemir, Bayram, Müller, Lutz Peter, Gliko-Kabir, Irit, Ludwig-Kraus, Beatrice, Edemir, Sabine, Sorani, Ella, Binder, Mascha, Vainstein, Abi, Kadosh, Shaul, Gromann, Cora, Wienke, Andreas, Baldus, Claudia D., Platzbecker, Uwe, Serve, Hubert, Bornhäuser, Martin, Junghanss, Christian, and Müller-Tidow, Carsten

Subjects
Immunology, ddc:610, Cell Biology, Hematology, Biochemistry
Published
2022

17. Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Data from A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, primary, Loirat, Delphine, primary, Lopez, Rafael Lopez, primary, Beck, J. Thaddeus, primary, De Laurentiis, Michelino, primary, Im, Seock-Ah, primary, Kim, Sung-Bae, primary, Kwong, Ava, primary, Steger, Guenther G., primary, Adelantado, Esther Zamora, primary, Duhoux, Francois P., primary, Greil, Richard, primary, Kuter, Irene, primary, Lu, Yen-Shen, primary, Tibau, Ariadna, primary, Özgüroğlu, Mustafa, primary, Scholz, Christian W., primary, Singer, Christian F., primary, Vega, Estela, primary, Wimberger, Pauline, primary, Zamagni, Claudio, primary, Couillebault, Xuan-Mai, primary, Fan, Liqiong, primary, Guerreiro, Nelson, primary, Mataraza, Jennifer, primary, Sand-Dejmek, Janna, primary, and Chan, Arlene, primary

Published
2023
Full Text
View/download PDF

19. Mobilization and Hematopoietic Stem Cell Collection in Poor Mobilizing Patients with Lymphoma: Final Results of the German OPTIMOB Study

Author

Kriegsmann, Katharina, primary, Bittrich, Max, additional, Sauer, Sandra, additional, Tietze-Stolley, Carola, additional, Movassaghi, Kamran, additional, Grube, Matthias, additional, Vucinic, Vladan, additional, Wehler, Daniela, additional, Burchert, Andreas, additional, Schmidt-Hieber, Martin, additional, Rank, Andreas, additional, Dürk, Heinz A., additional, Metzner, Bernd, additional, Kimmich, Christoph, additional, Hentrich, Marcus, additional, Kunz, Christian, additional, Hartmann, Frank, additional, Khandanpour, Cyrus, additional, de Wit, Maike, additional, Holtick, Udo, additional, Kiehl, Michael, additional, Stoltefuß, Andrea, additional, Kiani, Alexander, additional, Naumann, Ralph, additional, Scholz, Christian W., additional, Tischler, Hans-Joachim, additional, Görner, Martin, additional, Brand, Franziska, additional, Ehmer, Martin, additional, and Kröger, Nicolaus, additional

Published
2023
Full Text
View/download PDF

20. International validation of two EORTC questionnaires for assessment of health‐related quality of life for patients with high‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐HG29) and low‐grade non‐Hodgkin lymphoma (QLQ‐NHL‐LG20)

Author

Oerlemans, Simone, Efficace, Fabio, Kyriakou, Charalampia, Freitas, Ana Carolina, Shamieh, Omar, Creutzberg, Carien L., Lehmann, Jens, Petranovic, Duska, Nagele, Eva, Bredart, Anne, Dong, Dong, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Griškevičius, Laimonas, Xochelli, Aliki, Kieffer, Jacobien M., Agelink van Rentergem, Joost A., Alrjoub, Waleed, Mueller, Anja, Gomes Da Silva, Maria, Alves da Costa, Filipa, Malak, Sandra, Cocks, Kim, and van de Poll‐Franse, Lonneke V.

Subjects
EORTC, non‐Hodgkin lymphoma, PRO, psychometric properties, quality of life, questionnaire, symptoms
Abstract

Background: Health‐related quality of life (HRQOL) is a critical aspect to consider when making treatment decisions for patients with non‐Hodgkin‐lymphoma (NHL). This international study by the European Organisation for Research and Treatment of Cancer (EORTC) tested the psychometric properties of two newly developed measures for patients with high‐grade (HG)‐ and low‐grade (LG)‐NHL: the EORTC QLQ‐NHL‐HG29 and the EORTC QLQ‐NHL‐LG20 to supplement the core questionnaire (EORTC QLQ‐C30). Methods: Overall, 768 patients with HG‐NHL (N = 423) and LG‐NHL (N = 345) from 12 countries completed the QLQ‐C30, QLQ‐NHL‐HG29/QLQ‐NHL‐LG20 and a debriefing questionnaire at baseline, and a subset at follow‐up for either retest (N = 125/124) or responsiveness to change (RCA; N = 98/49). Results: Confirmatory factor analysis showed an acceptable to good fit of the 29 items of the QLQ‐NHL‐HG29 on its five scales (symptom burden [SB], neuropathy, physical condition/fatigue [PF], emotional impact [EI], and worries about health/ functioning [WH]), and of the 20 items of the QLQ‐NHL‐LG20 on its four scales (SB, PF, EI, and WH). Completion took on average 10 minutes. Test–retest reliability, convergent validity, known‐group comparisons, and RCA find satisfactory results of both measures. A total of 31%–78% of patients with HG‐NHL and 22%–73% of patients with LG‐NHL reported symptoms and/or worries (e.g., tingling in hands/ feet, lack of energy, and worries about recurrence). Patients reporting symptoms/ worries had substantially lower HRQOL compared to those without. Discussion: The use of the EORTC QLQ‐NHL‐HG29 and QLQ‐NHL‐LG20 questionnaires in clinical research and practice will provide clinically relevant data to better inform treatment decision‐making. Plain language summary � The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group developed two questionnaires. � These questionnaires measure health‐related quality of life. � The questionnaires are for patients with high‐grade or low‐grade non‐Hodgkin lymphoma. � They are called the EORTC QLQ‐NHL‐HG29 and QLQ‐NHL‐LG20. � The questionnaires are now internationally validated. � This study demonstrates that the questionnaires are reliably and valid, which are important aspects of a questionnaire. � The questionnaires can now be used in clinical trials and practice. � With the information gathered from the questionnaires, patients and clinicians can better evaluate treatments and discuss the best choice for a patient.

Published
2023

21. Controlled non‐randomised before–after study evaluating the impact of a focused recommendation card on vaccination rates of oncological patients—The Easy Vaccination in Oncology (EVO) strategy

Author

Kiderlen, Til R., primary, Trostdorf, Katrin, additional, Delmastro, Nicola, additional, Salomon, Arne, additional, Scholz, Christian W., additional, Späth‐Schwalbe, Ernst, additional, Mansmann, Veit, additional, Roll, Stephanie, additional, Reinwald, Mark, additional, and de Wit, Maike, additional

Published
2022
Full Text
View/download PDF

22. Poster: IBCL-123 inMIND: A Phase 3 Study of Tafasitamab Plus Lenalidomide and Rituximab Versus Placebo Plus Lenalidomide and Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Author

Sehn, Laurie H., primary, Hubel, Kai, additional, Luminari, Stefano, additional, Salar, Antonio, additional, Wahlin, Bjorn E., additional, Gopal, Ajay K., additional, Bonnet, Christophe, additional, Paneesha, Shankara, additional, Trneny, Marek, additional, Mashegu, Hafsat, additional, Lihou, Christine F., additional, Cheng, Lulu, additional, and Scholz, Christian W., additional

Published
2022
Full Text
View/download PDF

23. Raising immunization rates among cancer patients

Author

Kiderlen, Til R., primary, Trostdorf, Katrin, additional, Delmastro, Nicola, additional, Salomon, Arne, additional, Scholz, Christian W., additional, Späth-Schwalbe, Ernst, additional, Mansmann, Veit, additional, Roll, Stephanie, additional, Reinwald, Mark, additional, and de Wit, Maike, additional

Published
2022
Full Text
View/download PDF

25. inMIND: A phase 3 study of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab for relapsed/refractory follicular or marginal zone lymphoma.

Author

Sehn, Laurie Helen, primary, Hübel, Kai, additional, Luminari, Stefano, additional, Salar, Antonio, additional, Wahlin, Bjorn E., additional, Gopal, Ajay K., additional, Bonnet, Christophe Marc, additional, Paneesha, Shankara, additional, Trneny, Marek, additional, Mashegu, Hafsat Umar, additional, Lihou, Christine Francis, additional, Li, Di, additional, and Scholz, Christian W., additional

Published
2022
Full Text
View/download PDF

26. CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.

Author

Nastoupil, Loretta J., primary, Morschhauser, Franck, additional, Scholz, Christian W., additional, Bishton, Mark, additional, Yoon, Sung-Soo, additional, Giri, Pratyush, additional, Wei, Michael C., additional, Knapp, Andrea, additional, Li, Chi-Chung, additional, Bottos, Alessia, additional, Li, Haocheng, additional, Purev, Enkhtsetseg, additional, and Bartlett, Nancy L., additional

Published
2022
Full Text
View/download PDF

27. International validation of the questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia

Author

Oerlemans, Simone, Efficace, Fabio, Kieffer, Jacobien M., Kyriakou, Charalampia, Xochelli, Aliki, Levedahl, Kerstin, Petranović, Duška, Borges, Fabio Cardoso, Bredart, Anne, Shamieh, Omar, Gziskevicius, Laimonas, Lehmann, Jens, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Stamatopoulos, Kostas, Panteliadou, Alkistis‐Kyra, Papaioannou, Maria, Alrjoob, Waleed, Baliakas, Panagiotis, Rosenquist, Richard, Malak, Sandra, Miranda, Ana, Cocks, Kim, and Poll‐Franse, Lonneke

Subjects
PRO, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, EORTC, quality of life, questionnaire, symptoms, social sciences, psychometric properties, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, humanities, chronic lymphocytic leukaemia
Abstract

Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient-reported health-related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ-CLL17 to supplement the core questionnaire (EORTC QLQ-C30). Patients with CLL (n = 341) from 12 countries completed the QLQ-C30, QLQ-CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%-66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test-retest and convergent validity was demonstrated. The QLQ-CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1-3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ-CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision-making.

Published
2022

29. A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Author

Kuemmel, Sherko, primary, Campone, Mario, additional, Loirat, Delphine, additional, Lopez, Rafael Lopez, additional, Beck, J. Thaddeus, additional, De Laurentiis, Michelino, additional, Im, Seock-Ah, additional, Kim, Sung-Bae, additional, Kwong, Ava, additional, Steger, Guenther G., additional, Adelantado, Esther Zamora, additional, Duhoux, Francois P., additional, Greil, Richard, additional, Kuter, Irene, additional, Lu, Yen-Shen, additional, Tibau, Ariadna, additional, Özgüroğlu, Mustafa, additional, Scholz, Christian W., additional, Singer, Christian F., additional, Vega, Estela, additional, Wimberger, Pauline, additional, Zamagni, Claudio, additional, Couillebault, Xuan-Mai, additional, Fan, Liqiong, additional, Guerreiro, Nelson, additional, Mataraza, Jennifer, additional, Sand-Dejmek, Janna, additional, and Chan, Arlene, additional

Published
2022
Full Text
View/download PDF

30. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study

Author

Klamroth, Robert, primary, Sinn, Marianne, additional, Pollich, Christiane, additional, Bischoff, Sven, additional, Lohneis, Anja, additional, Orlovic, Ana-Marija, additional, Wisłocka, Lilianna, additional, Habbel, Piet, additional, de Wit, Maike, additional, Späth-Schwalbe, Ernst, additional, Scholz, Christian W., additional, and Riess, Hanno, additional

Published
2021
Full Text
View/download PDF

31. IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Author

Sehn, Laurie H., primary, Scholz, Christian W., additional, Luminari, Stefano, additional, Salar, Antonio, additional, Wahlin, Björn E., additional, Gopal, Ajay K., additional, Bonnet, Christophe, additional, Trneny, Marek, additional, Paneesha, Shankara, additional, Manzke, Oliver, additional, Seguy, Francis, additional, Li, Di, additional, and Hübel, Kai, additional

Published
2021
Full Text
View/download PDF

32. Poster: IBCL-131: inMIND: A Phase 3 Study of Tafasitamab + Lenalidomide Add-On to Rituximab vs Placebo + Lenalidomide Add-On to Rituximab for Relapsed/Refractory (R/R) Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL)

Author

Sehn, Laurie H., primary, Scholz, Christian W., additional, Luminari, Stefano, additional, Salar, Antonio, additional, Wahlin, Björn E., additional, Gopal, Ajay K., additional, Bonnet, Christophe, additional, Trneny, Marek, additional, Paneesha, Shankara, additional, Manzke, Oliver, additional, Seguy, Francis, additional, Li, Di, additional, and Hübel, Kai, additional

Published
2021
Full Text
View/download PDF

37. A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Author

Sehn, Laurie Helen, primary, Scholz, Christian W, additional, Luminari, Stefano, additional, Salar, Antonio, additional, Wahlin, Bjorn E., additional, Gopal, Ajay K., additional, Bonnet, Christophe Marc, additional, Paneesha, Shankara, additional, Manzke, Oliver, additional, Seguy, Francis, additional, Li, Di, additional, and Hübel, Kai, additional

Published
2021
Full Text
View/download PDF

38. International validation of the EORTC QLQ‐CLL17 questionnaire for assessment of health‐related quality of life for patients with chronic lymphocytic leukaemia.

Author

Oerlemans, Simone, Efficace, Fabio, Kieffer, Jacobien M., Kyriakou, Charalampia, Xochelli, Aliki, Levedahl, Kerstin, Petranovic, Duska, Borges, Fabio Cardoso, Bredart, Anne, Shamieh, Omar, Gziskevicius, Laimonas, Lehmann, Jens, Scholz, Christian W., Caocci, Giovanni, Molica, Stefano, Stamatopoulos, Kostas, Panteliadou, Alkistis‐Kyra, Papaioannou, Maria, Alrjoob, Waleed, and Baliakas, Panagiotis

Subjects
LYMPHOCYTIC leukemia, QUALITY of life, CONFIRMATORY factor analysis, CHRONIC leukemia, PSYCHOMETRICS, MEDICAL research
Abstract

Summary: Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient‐reported health‐related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ‐CLL17 to supplement the core questionnaire (EORTC QLQ‐C30). Patients with CLL (n = 341) from 12 countries completed the QLQ‐C30, QLQ‐CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%–66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test–retest and convergent validity was demonstrated. The QLQ‐CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1–3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ‐CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision‐making. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

39. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.

Author

Klamroth, Robert, Sinn, Marianne, Pollich, Christiane, Bischoff, Sven, Lohneis, Anja, Orlovic, Ana-Marija, Wisłocka, Lilianna, Habbel, Piet, de Wit, Maike, Späth-Schwalbe, Ernst, Scholz, Christian W., and Riess, Hanno

Subjects
VENOUS thrombosis, PATIENT compliance, LOW-molecular-weight heparin, ANTICOAGULANTS, HOSPITAL admission & discharge
Abstract

Introduction: Cancer-associated venous thrombosis (CAT) is a common and serious complication of active malignancies, increasing in frequency during systemic treatment and radiotherapy. Due to a high risk of recurrence and bleeding, the administration of anticoagulants for initial treatment and secondary prevention of CAT is challenging. We conducted a prospective registry study of patients with acute CAT to evaluate the way treatment is given to these patients in routine practice. Methods: From May 2015 to May 2017, all consecutive patients with acute venous thromboembolism (VTE) admitted to specialty or emergency departments of the participating hospitals in Berlin, Germany, were entered into the registry. Patients with cancer underwent extensive baseline evaluation including the type and location of thrombosis and use of anticoagulant therapy. Follow-up assessments were made at discharge and by telephone interviews at 3 and 6 months. Results: A total of 382 patients with acute CAT were enrolled in the study, representing 24.5% of all patients with thrombosis. 70.4% of CAT patients had deep vein thromboses (DVT), 48.2% had pulmonary embolism (PE), and 18.6% had concurrent PE and DVT. A significant proportion of VTE (27%) was asymptomatic and was diagnosed only incidentally. At baseline, 97.9% of the patients received anticoagulant therapy, predominantly with low-molecular-weight heparin (LMWH) (n = 334, 87.4%). Direct oral anticoagulants (DOACs) were given to 5.8% of patients, and vitamin K antagonists were rarely used (<2% of patients). Changes in the prescription of antithrombotic agents were seen at discharge from hospital and during follow-up. Overall, the use of LMWH declined during follow-up, while the proportion of patients treated with DOACs increased to 32.4% at 6 months. At baseline, the most frequently used LMWH were enoxaparin and nadroparin, but many patients were switched to once daily tinzaparin prior to discharge. Initially and after discharge, the majority of patients were treated by oncologists. Overall, 263 (68.8%) and 222 (58.1%) patients were still alive and could be contacted at 3 and 6 months of follow-up, respectively. Of these, 84.0% and 71.6% were still on anticoagulant therapy (58.6% and 36.5% on LMWH). Conclusion: In accordance with the guidelines, the majority of CAT patients received anticoagulation therapy for the recommended minimum duration of 3–6 months. LMWH remained the preferred option throughout the study, demonstrating good patient adherence. In deviation from guideline recommendations and available study results during the study period, more than a quarter of CAT patients were treated with DOACs. Only recently, DOACs have been established as another option for anticoagulation in CAT patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

45. GECAT - German Evaluation of Cancer Associated Thrombosis: A Prospective Register Trial for Patients with Active Cancer and Venous Thromboembolism (VTE) in Berlin

Author

Sinn, Marianne, primary, Pollich, Christiane, additional, Riess, Hanno, additional, Bischoff, Sven, additional, Habbel, Piet, additional, Scholz, Christian W, additional, Spaeth-Schwalbe, Ernst, additional, de Wit, Maike, additional, Jühling, Anja, additional, Wolter, Eike, additional, Wislocka, Lilianna, additional, and Klamroth, Dr., additional

Published
2019
Full Text
View/download PDF

47. Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8‐year follow‐up data of 281 patients from the international RIT‐registry

Author

Hohloch, Karin, primary, Windemuth‐Kieselbach, Christiane, additional, Kolz, Julia, additional, Zinzani, Pier Luigi, additional, Cacchione, Roberto, additional, Jurczak, Woijciech, additional, Bischof Delaloye, Angelika, additional, Trümper, Lorenz, additional, and Scholz, Christian W., additional

Published
2018
Full Text
View/download PDF

48. Radioimmunotherapy for Follicular Lymphoma Achieves Long Term Lymphoma Control in First Line and at Relapse: 8 Year Follow Up Data of 281 Patients from the International RIT-Registry

Author

hohloch, karin, primary, Windemuth-Kiesselbach, Christiane, additional, Kolz, Julia, additional, Zinzani, Pier L., additional, Caccione, Roberto, additional, Jurczak, Woijciech, additional, Bischof-Delalaoye, Angelika, additional, Truemper, Lorenz, additional, and Scholz, Christian W., additional

Published
2018
Full Text
View/download PDF

49. 90Yttrium-Ibritumomab Tiuxetan as First Line Treatment for Follicular Non-Hodgkin Lymphoma. 5 Year Results from an International Multicenter Phase II Clinical Trial

Author

Lerch, Kristina, primary, Leng, Corinna, additional, Pinto, Antonello, additional, Linkesch, Werner, additional, Sill, Heinz, additional, Linden, Ola, additional, Viardot, Andreas, additional, Keller, Ulrich, additional, Hess, Georg, additional, Lastoria, Secondo, additional, Frigeri, Ferdinando, additional, Neik, Nicole, additional, Pott, Christiane, additional, Scholz, Christian W., additional, and Pezzutto, Antonio, additional

Published
2016
Full Text
View/download PDF

50. Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8‐year follow‐up data of 281 patients from the international RIT‐registry.

Author

Hohloch, Karin, Windemuth‐Kieselbach, Christiane, Kolz, Julia, Zinzani, Pier Luigi, Cacchione, Roberto, Jurczak, Woijciech, Bischof Delaloye, Angelika, Trümper, Lorenz, and Scholz, Christian W.

Subjects
LYMPHOMAS, RADIOIMMUNOTHERAPY
Abstract

Summary: To assess efficacy of radioimmunotherapy (RIT) in follicular lymphoma, data from 281 patients collected in the RIT Network, with a median follow‐up of 8·2 years after RIT were analysed. RIT was given at first line in 18·5% and at relapse in 81·5%. Following first line therapy, 76·9% achieved complete remission (CR), 9·6% partial remission (PR), 1·9% stable disease (SD) and 1·9% had progressive disease (PD); response was not documented in 9·7%. At relapse, the rate of CR was 48·5% and that of PR was 16·6%, SD 2·6% and PD 10·5%; response was not documented in 21·8%. After median follow‐up of 8·2 years, median progression‐free survival (PFS) for all was 2·54 years, median overall survival (OS) was not reached. Median PFS and OS (both not reached) were significantly better in first line, compared to RIT at relapse (PFS, 2·11 years; OS, 10·8 years; P = 0·0037 and P = 0·0021, respectively). Overall 8‐year PFS was 33·9%, 53·6% for first line and 29·6% for relapsed individuals. Overall 8‐year OS was 58·8%, 78·1% for first line and 54·5% for relapsed patients. Thirty‐five patients (12·5%) developed secondary malignancy and 16 patients (5·7%) experienced transformation into aggressive lymphoma. RIT is a safe and effective treatment option for follicular lymphoma, both at front line and relapse with an 8‐year PFS of 53·6% and 29·6%, respectively. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results